Doc who said GSK tried to silence him will testify during Avandia hearing
Pharma Compliance Alert, June 6, 2007
When a congressional committee digs into the safety of GlaxoSmithKline's diabetes drug Avandia this week it will hear from a prominent physician who says GSK tried to stifle his criticism of the drug.
Dr. John B. Buse, in line to become the American Diabetes Association president, wrote to the FDA in 2000 about his concerns that Avandia might increase heart attack risk, reports The New York Times. However, in a statement published by The Times, Buse says that he was "intimidated" in 1999 by the company and that GSK later apologized. He did not elaborate on the nature of the intimidation, instead saying he would tell the entire story during his testimony, reports The Times.
Last chance to take our survey!
How is your company dealing with the issue of rep credentialing? Click here to take our fast, confidential survey and receive our free white paper on hospital requirements for credentialing healthcare industry representatives.
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Big Pharma Performance Before, During and Beyond the Global Recession
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- What does case-mix index mean to you?
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Searched